Abcam, ab282594, Anti-KMT3C / SMYD2 antibody [EPR24071-25] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal KMT3C / SMYD2 antibody. Carrier free. Suitable for ICC/IF, IP, WB, Flow Cyt (Intra) and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR24071-25,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:WB, Flow Cyt (Intra), IP, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab282594 is the carrier-free version of
ab259973
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
KMT3C also known as SMYD2 is a lysine methyltransferase enzyme that possesses a unique SET domain responsible for catalyzing the methylation of lysine residues on histone and non-histone proteins. The enzyme has a molecular mass of approximately 52 kDa. SMYD2 shows expression in various tissues including heart skeletal muscle and also liver. It methylates histone H3 on lysine 36 (H3K36) and several non-histone proteins influencing gene expression regulation and protein function.
Biological function summary
KMT3C/SMYD2 plays important roles in gene regulation and cellular processes. It functions as a part of a protein complex affecting transcriptional activation and repression via chromatin remodeling. The methylation activity of SMYD2 extends to p53 an important tumor suppressor linking it to the regulation of cell cycle and apoptosis. This enzymatic activity impacts cellular growth and differentiation interfacing with the larger network of cellular gene expression control and protein function modulation.
Pathways
Research shows KMT3C/SMYD2 being active in the p53 and AKT signaling pathways fundamental to cell survival proliferation and apoptosis. In the context of the p53 pathway SMYD2 methylates p53 which may impact its tumor suppressor functions. SMYD2 also interacts with proteins like RB1 and HDAC1 integrating into broader cell regulatory networks. These interactions facilitate SMYD2's influence on pathways that govern important cellular processes such as growth and DNA damage response.
Mutations and overexpression of KMT3C/SMYD2 associate with various cancers including breast and esophageal cancer. In the case of breast cancer SMYD2 modulates p53 and RB1 activity contributing to tumorigenesis. Furthermore its interaction with HDAC1 connects it with epigenetic dysregulation seen in cancer progression. Altered activity or expression of SMYD2 disrupts normal cellular function providing a link between its biological activity and oncogenic processes.